Belatacept [Nulojix]: Increased Risk of Post-Transplant Lymphoproliferative Disorder (PTLD) and Progressive Multifocal Leukoencephalopathy (PML)

Last Updated on

July 7, 2011 – Bristol-Myers Squibb (BMS) today informed healthcare professionals about a REMS (Risk Evaluation and Mitigation Strategy) that is required for Belatacept [Nulojix] to ensure that the benefits of Belatacept [Nulojix] outweigh the risks of Post-Transplant Lymphoproliferative Disorder (PTLD) and Progressive Multifocal Leukoencephalopathy (PML), both of which can be fatal. Patients treated with Belatacept [Nulojix] are at an increased risk for developing PTLD, predominantly involving the CNS. PML has been reported in patients receiving Belatacept [Nulojix] at higher than recommended doses as part of an immunosuppressant regimen.

The American Food and Drug Administration (FDA) may require a REMS from a manufacturer before approval or post approval to ensure that the benefits of a drug or biological product outweigh its risks. Belatacept [Nulojix] is a selective T-cell costimulation blocker recently approved for prophylaxis of organ rejection in adult patients receiving a kidney transplant. Belatacept [Nulojix] is to be used in combination with basiliximab induction, mycophenolate mofetil (MMF), and corticosteroids. Belatacept [Nulojix] is indicated for use only in transplant patients who are Epstein-Barr virus (EBV) seropositive. Use in liver transplant patients is not recommended due to an increased risk of graft loss and death. Use of Belatacept [Nulojix] for the prophylaxis of organ rejection in other transplanted organs has not been established.

Be sure to verify the patient’s EBV status before initiating therapy with Belatacept [Nulojix]. BMS established the ENLiST Registry to further evaluate the safety profile of Belatacept [Nulojix]. BMS encourages your participation in the ENLiST Registry.

View here the  original article

Tags: , , ,
About the Author
Joseph Gut - thasso Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.
1 Pings/Trackbacks for "Belatacept [Nulojix]: Increased Risk of Post-Transplant Lymphoproliferative Disorder (PTLD) and Progressive Multifocal Leukoencephalopathy (PML)"

Your opinion

Comment

No comments yet

thasso: conditions

thasso: newest tweets

thasso: recent comments

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Spatial mapping method pinpoints potential new therapeutic targets in lupus July 8, 2020
    A team of researchers from Children's Hospital of Philadelphia (CHOP) used a new method of pinpointing potential disease-causing changes in the genome to identify two new potential therapeutic targets for lupus, while also paving the way for more accurately identifying disease-causing variations in other autoimmune disorders. The findings were published online in Nature Communications.
  • New clues to lung-scarring disease may aid treatment July 8, 2020
    Scientists at Vanderbilt University Medical Center (VUMC) and the Translational Genomics Research Institute (TGen) in Phoenix, Arizona, have discovered previously unreported genetic and cellular changes that occur in the lungs of people with pulmonary fibrosis (PF).
  • Abnormal cells in early-stage embryos might not preclude IVF success July 8, 2020
    The presence of an abnormal number of chromosomes in the genetic profile of early-stage embryos may be far more common—and potentially less threatening—during normal human development than is currently appreciated, according to new research from Johns Hopkins University biologists.
  • Huntington disease brain changes ID'd 24 years before symptoms July 8, 2020
    (HealthDay)—The earliest brain changes due to Huntington disease (HD) can be detected in cerebrospinal fluid (CSF) 24 years before clinical symptoms show, according to a study published in the June 1 issue of The Lancet Neurology.
  • Metabolomics meets genomics to improve patient diagnosis July 7, 2020
    A patient and family walk into a doctor's office. They hope that the latest tests will reveal what is causing the patient's illness and end the diagnostic odyssey they have been going through for years. Having an accurate diagnosis also means that maybe there is a treatment that at least can alleviate the patient's condition.
Top